Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma.

about

Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma.

Item

http://www.wikidata.org/entity/Q50638576

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Development and validation of ...... three antitumorals in plasma.

@en

Development and validation of ...... three antitumorals in plasma.

@nl

type

Item

label

Development and validation of ...... three antitumorals in plasma.

@en

Development and validation of ...... three antitumorals in plasma.

@nl

prefLabel

Development and validation of ...... three antitumorals in plasma.

@en

Development and validation of ...... three antitumorals in plasma.

@nl

P1476

Development and validation of ...... three antitumorals in plasma.

@en

P2093

Enrique Ochoa-Aranda

http://www.w3.org/2001/XMLSchema#string

Jaume Albiol Chiva

http://www.w3.org/2001/XMLSchema#string

Josep Esteve Romero

http://www.w3.org/2001/XMLSchema#string

Juan Peris-Vicente

http://www.w3.org/2001/XMLSchema#string

P2860

DrugBank 4.0: shedding new light on drug metabolism

Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Quantitative determination of regorafenib and its two major metabolites in human plasma with high-performance liquid chromatography and ultraviolet detection.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

A review on development of analytical methods to determine monitorable drugs in serum and urine by micellar liquid chromatography using direct injection.

P304

799-812

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/BIO-2017-0028

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28520456

http://www.w3.org/2001/XMLSchema#string